1. Home
  2. CNXN vs URGN Comparison

CNXN vs URGN Comparison

Compare CNXN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PC Connection Inc.

CNXN

PC Connection Inc.

HOLD

Current Price

$80.79

Market Cap

2.0B

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$47.11

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXN
URGN
Founded
1982
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
CNXN
URGN
Price
$80.79
$47.11
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.29
AVG Volume (30 Days)
142.7K
795.1K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
1.26%
N/A
EPS Growth
N/A
N/A
EPS
1.99
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$6.24
$129.09
Revenue Next Year
$4.39
$70.96
P/E Ratio
$41.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.97
$15.86
52 Week High
$88.31
$48.19

Technical Indicators

Market Signals
Indicator
CNXN
URGN
Relative Strength Index (RSI) 51.58 67.57
Support Level $56.57 $18.23
Resistance Level $88.31 N/A
Average True Range (ATR) 3.13 2.39
MACD -0.48 0.35
Stochastic Oscillator 14.47 86.58

Price Performance

Historical Comparison
CNXN
URGN

About CNXN PC Connection Inc.

PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: